Immuno-oncology company Portage Biotech to evaluate strategic alternatives
Clinical-stage immuno-oncology company Portage Biotech has announced plans to expand its assessment of strategic alternatives.
Clinical-stage immuno-oncology company Portage Biotech has announced plans to expand its assessment of strategic alternatives.
AGC Biologics has completed the facility expansion for its new plasmid DNA (pDNA) and messenger RNA (mRNA) production line at Heidelberg, Germany.
China-based biotech company Therorna has secured $42m in a Series A financing round to support its growth and fuel product pipeline development.
Biotechnology firm Inceptor Bio has raised $37m from Series A funding round that was led by Kineticos Ventures.
Massachusetts-based Arbor Biotechnologies has raised $215m through Series B financing round, and plans to use the proceeds to advance its next-generation precision editing therapeutics.
Biotechnology company Prime Medicine has launched with $315m funding to advance its Prime Editing platform, a next-generation gene editing technology.
A branch of the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID) has granted $2.5m to 12 institutes across the world for bacteriophage therapy research.
Akron Biotechnology (Akron Biotech) has signed an exclusive global agreement with Swiss-based Octapharma, to manufacture virally inactivated Human AB Serum for the cell therapy market.
Chinese biotechnology firm Cure Genetics has partnered with Boehringer Ingelheim for the development of novel Adeno-Associated Virus (AAV) vectors to be used in gene therapies.